Clonidine hydrochloride (HCl) extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14) ] .
Clonidine HCl extended-release tablets are an extended-release tablet to be taken orally with or without food. Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of clonidine release. Due to the lack of controlled clinical trial data and differing pharmacokinetic profiles, substitution of clonidine HCl extended-release tablets for other clonidine products on a mg-per-mg...
Clonidine HCl extended-release tablets, 0.1 mg, are supplied as white, round biconvex tablets, debossed "A" over “16” on one side and plain on the other side. They are available as follows: Bottles of 60: NDC 69238-1426-6 Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight container.
www.fda.gov/medwatch
womensmentalhealth.org/adhd-medicationswomensmentalhealth.org/adhdmedications
www.amneal.comClonidine hydrochloride (HCl) extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)].
Clonidine HCl extended-release tablets are an extended-release tablet to be taken orally with or without food. Swallow tablets whole. Do not crush, chew, or break tablets because this will increase the rate of clonidine release.
Due to the lack of controlled clinical trial data and differing pharmacokinetic profiles, substitution of clonidine HCl extended-release tablets for other clonidine products on a mg-per-mg basis is not recommended [see Clinical Pharmacology (12.3)].
The dose of clonidine HCl extended-release tablets, administered either as monotherapy or as adjunctive therapy to a psychostimulant, should be individualized according to the therapeutic needs and response of the patient. Dosing should be initiated with one 0.1 mg tablet at bedtime, and the daily dosage should be adjusted in increments of 0.1 mg/day at weekly intervals until the desired response is achieved. Doses should be taken twice a day, with either an equal or higher split dosage being given at bedtime (see Table 1).
Table 1 Clonidine HCl Extended-Release Tablets Dosing Guidance
Total Daily Dose | Morning Dose | Bedtime Dose |
0.1 mg/day | 0.1 mg | |
0.2 mg/day | 0.1 mg | 0.1 mg |
0.3 mg/day | 0.1 mg | 0.2 mg |
0.4 mg/day | 0.2 mg | 0.2 mg |
Doses of clonidine HCl extended-release tablets higher than 0.4 mg/day (0.2 mg twice daily) were not evaluated in clinical trials for ADHD and are not recommended.
When clonidine HCl extended-release tablets are being added-on to a psychostimulant, the dose of the psychostimulant can be adjusted depending on the patient's response to clonidine HCl extended-release tablets.
When discontinuing clonidine HCl extended-release tablets, the total daily dose should be tapered in decrements of no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension [see Warnings and Precautions (5.3)].
If patients miss a dose of clonidine HCl extended-release tablets, they should skip that dose and take the next dose as scheduled. Do not take more than the prescribed total daily amount of clonidine HCl extended-release tablets in any 24-hour period.
Clonidine HCl extended-release tablets are available in one strength, 0.1 mg as an extended-release formulation. The 0.1 mg tablets are white, round biconvex tablets debossed “A” over “16” on one side and plain on other side. Clonidine HCl extended-release tablets must be swallowed whole and never crushed, cut or chewed.
Clonidine HCl extended-release tablets are contraindicated in patients with a history of a hypersensitivity reaction to clonidine. Reactions have included generalized rash, urticaria, and angioedema [see Adverse Reactions (6)].
Treatment with clonidine HCl extended-release can cause dose-related decreases in blood pressure and heart rate [see Adverse Reactions (6.1)]. Measure heart rate and blood pressure prior to initiation of therapy, following dose increases, and periodically while on therapy. Titrate clonidine HCl extended-release slowly in patients with a history of hypotension, and those with underlying conditions that may be worsened by hypotension and bradycardia; e.g., heart block, bradycardia, cardiovascular disease, vascular disease, cerebrovascular disease, or chronic renal failure. In patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, advise patients to avoid becoming dehydrated or overheated. Monitor blood pressure and heart rate, and adjust dosages accordingly in patients treated concomitantly with antihypertensives or other drugs that can reduce blood pressure or heart rate or increase the risk of syncope.
Somnolence and sedation were commonly reported adverse reactions in clinical studies. In patients that completed 5 weeks of therapy in a controlled, fixed dose pediatric monotherapy study, 31% of patients treated with 0.4 mg/day and 38% treated with 0.2 mg/day versus 4% of placebo treated patients reported somnolence as an adverse event. In patients that completed 5 weeks of therapy in a controlled flexible dose pediatric adjunctive to stimulants study, 19% of patients treated with clonidine HCl extended-release+stimulant versus 7% treated with placebo+stimulant reported somnolence. Before using clonidine HCl extended-release with other centrally active depressants (such as phenothiazines, barbiturates, or benzodiazepines), consider the potential for additive sedative effects. Caution patients against operating heavy equipment or driving until they know how they respond to treatment with clonidine HCl extended-release. Advise patients to avoid use with alcohol.
Abrupt discontinuation of clonidine HCl extended-release can cause rebound hypertension. In adults with hypertension, sudden cessation of clonidine hydrochloride extended-release formulation treatment in the 0.2 to 0.6 mg/day range resulted in reports of headache, tachycardia, nausea, flushing, warm feeling, brief lightheadedness, tightness in chest, and anxiety. In adults with hypertension, sudden cessation of treatment with immediate-release clonidine has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma.
No studies evaluating abrupt discontinuation of clonidine HCl extended-release in children with ADHD have been conducted; however, to minimize the risk of rebound hypertension, gradually reduce the dose of clonidine HCl extended-release in decrements of no more than 0.1 mg every 3 to 7 days. Patients should be instructed not to discontinue clonidine HCl extended-release therapy without consulting their physician due to the potential risk of withdrawal effects.
In patients who have developed localized contact sensitization to clonidine transdermal system, continuation of clonidine transdermal system or substitution of oral clonidine HCl extended-release therapy may be associated with the development of a generalized skin rash.
In patients who develop an allergic reaction from clonidine transdermal system, substitution of oral clonidine HCl extended-release may also elicit an allergic reaction (including generalized rash, urticaria, or angioedema).
The sympatholytic action of clonidine may worsen sinus node dysfunction and atrioventricular (AV) block, especially in patients taking other sympatholytic drugs. There have been post-marketing reports of patients with conduction abnormalities and/or taking other sympatholytic drugs who developed severe bradycardia requiring IV atropine, IV isoproterenol, and temporary cardiac pacing while taking clonidine. Titrate clonidine HCl extended-release slowly and monitor vital signs frequently in patients with cardiac conduction abnormalities or patients concomitantly treated with other sympatholytic drugs.
The following serious adverse reactions are described in greater detail elsewhere in labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Two clonidine HCl extended-release ADHD clinical studies (Study 1, CLON-301 and Study 2, CLON-302) evaluated 256 patients in two 8-week placebo-controlled studies.
A third clonidine HCl extended-release ADHD clinical study (Study 3, SHN-KAP-401) evaluated 135 children and adolescents in a 40- week placebo-controlled randomized-withdrawal study.
Study 1: Fixed-dose Clonidine HCl Extended-Release Monotherapy
Study 1 (CLON-301) was a short-term, multi-center, randomized, double-blind, placebo-controlled study of two fixed doses (0.2 mg/day or 0.4 mg/day) of clonidine HCl extended-release in children and adolescents (6 to 17 years of age) who met DSM-IV criteria for ADHD hyperactive or combined inattentive/hyperactive subtypes.
Most Common Adverse Reactions (incidence of ≥ 5% and at least twice the rate of placebo): somnolence, fatigue, irritability, insomnia, nightmare, constipation, dry mouth.
Adverse Events Leading to Discontinuation of Clonidine HCl Extended-Release – Five patients (7%) in the low dose group (0.2 mg), 15 patients (20%) in the high dose group (0.4 mg), and 1 patient in the placebo group (1%) reported adverse reactions that led to discontinuation. The most common adverse reactions that led to discontinuation were somnolence and fatigue.
Commonly observed adverse reactions (incidence of ≥2% in either active treatment group and greater than the rate on placebo) during the treatment period are listed in Table 2.
Table 2 Common Adverse Reactions in the Fixed-Dose Monotherapy Trial - Treatment Period (Study 1)
| Percentage of Patients Reporting Event | |||
Preferred Term | Clonidine HCl
Extended-Release 0.2 mg/day N=76 | Clonidine HCl Extended-Release 0.4 mg/day N=78 | Placebo |
| PSYCHIATRIC DISORDERS Somnolence* Nightmare Emotional Disorder Aggression Tearfulness Enuresis Sleep Terror Poor Quality Sleep | 38% | 31% | 4% |
| NERVOUS SYSTEM DISORDERS Headache Insomnia Tremor Abnormal Sleep-Related Event | 20% | 13% | 16% |
| GASTROINTESTINAL DISORDERS Upper Abdominal Pain Nausea Constipation Dry Mouth | 15% | 10% | 12% |
| GENERAL DISORDERS Fatigue† Irritability | 16% | 13% | 1% |
| CARDIAC DISORDERS Dizziness Bradycardia | 7% | 3% | 5% |
INVESTIGATIONS | 0% | 3% | 0% |
| METABOLISM AND NUTRITION DISORDERS Decreased Appetite | 3% | 4% | 4% |
* Somnolence includes the terms "somnolence" and "sedation".
† Fatigue includes the terms "fatigue" and "lethargy".
Commonly observed adverse reactions (incidence of ≥2% in either active treatment group and greater than the rate on placebo) during the taper period are listed in Table 3.
Table 3 Common Adverse Reactions in the Fixed-Dose Monotherapy Trial - Taper Period* (Study 1)
| Percentage of Patients Reporting Event | |||
Preferred Term | Clonidine HCl Extended-Release | Clonidine HCl Extended-Release | Placebo |
| Abdominal Pain Upper | 0% | 6% | 3% |
| Headache | 5% | 2% | 3% |
| Gastrointestinal Viral | 0% | 5% | 0% |
| Somnolence | 2% | 3% | 0% |
| Heart Rate Increased | 0% | 3% | 0% |
| Otitis Media Acute | 3% | 0% | 0% |
* Taper Period: 0.2 mg dose, week 8; 0.4 mg dose, weeks 6 to 8; Placebo dose, weeks 6 to 8
Study 2: Flexible-dose Clonidine HCl Extended-Release as Adjunctive Therapy to Psychostimulants
Study 2 (CLON-302) was a short-term, randomized, double-blind, placebo-controlled study of a flexible dose of clonidine HCl extended-release as adjunctive therapy to a psychostimulant in children and adolescents (6 to 17 years) who met DSM-IV criteria for ADHD hyperactive or combined inattentive/hyperactive subtypes during which clonidine HCl extended-release was initiated at 0.1 mg/day and titrated up to 0.4 mg/day over a 3-week period. Most clonidine HCl extended-release treated patients (75.5%) were escalated to the maximum dose of 0.4 mg/day.
Most Common Adverse Reactions (incidence of ≥ 5% and at least twice the rate of placebo): somnolence, fatigue, decreased appetite, dizziness.
Adverse Events Leading to Discontinuation – There was one patient in the CLON+STM group (1%) who discontinued because of an adverse event (severe bradyphrenia, with severe fatigue).
Commonly observed adverse reactions (incidence of ≥2% in the treatment group and greater than the rate on placebo) during the treatment period are listed in Table 4.
Table 4 Common Adverse Reactions in the Flexible-Dose Adjunctive to Stimulant Therapy Trial - Treatment Period (Study 2)
Preferred Term | Percentage of Patients Reporting Event | |
Clonidine HCl Extended-Release+STM (N=102) | PBO+STM (N=96) | |
PSYCHIATRIC DISORDERS Somnolence* Aggression Affect Lability Emotional Disorder | 19% 2% 2% 2% | 7% 1% 1% 0% |
GENERAL DISORDERS Fatigue† Irritability | 14% 2% | 4% 7% |
NERVOUS SYSTEM DISORDERS Headache Insomnia | 7% 4% | 12% 3% |
GASTROINTESTINAL DISORDERS Upper Abdominal Pain | 7% | 4% |
RESPIRATORY DISORDERS Nasal Congestion | 2% | 2% |
METABOLISM AND NUTRITION DISORDERS Decreased Appetite | 6% | 3% |
CARDIAC DISORDERS Dizziness | 5% | 1% |
* Somnolence includes the terms: "somnolence" and "sedation".
† Fatigue includes the terms "fatigue" and "lethargy".
Commonly observed adverse reactions (incidence of ≥2% in the treatment group and greater than the rate on placebo) during the taper period are listed in Table 5.
Table 5 Common Adverse Reactions in the Flexible-Dose Adjunctive to Stimulant Therapy Trial - Taper Period* (Study 2)
Preferred Term | Percentage of Patients Reporting Event | |
Clonidine HCl Extended-Release+STM (N=102) | PBO+STM (N=96) | |
Nasal Congestion | 4% | 2% |
Headache | 3% | 1% |
Irritability | 3% | 2% |
Throat Pain | 3% | 1% |
Gastroenteritis Viral | 2% | 0% |
Rash | 2% | 0% |
* Taper Period: weeks 6 to 8
Adverse Reactions Leading to Discontinuation
Thirteen percent (13%) of patients receiving clonidine HCl extended-release discontinued from the pediatric monotherapy study due to adverse events, compared to 1% in the placebo group. The most common adverse reactions leading to discontinuation of clonidine HCl extended-release monotherapy treated patients were from somnolence/sedation (5%) and fatigue (4%).
Effect on Blood Pressure and Heart Rate
In patients that completed 5 weeks of treatment in a controlled, fixed-dose monotherapy study in pediatric patients, during the treatment period the maximum placebo-subtracted mean change in systolic blood pressure was -4.0 mmHg on clonidine HCl extended-release 0.2 mg/day and -8.8 mmHg on clonidine HCl extended-release 0.4 mg/day. The maximum placebo-subtracted mean change in diastolic blood pressure was -4.0 mmHg on clonidine HCl extended-release 0.2 mg/day and -7.3 mmHg on clonidine HCl extended-release 0.4 mg/day. The maximum placebo-subtracted mean change in heart rate was -4.0 beats per minute on clonidine HCl extended-release 0.2 mg/day and -7.7 beats per minute on clonidine HCl extended-release 0.4 mg/day.
During the taper period of the fixed-dose monotherapy study the maximum placebo-subtracted mean change in systolic blood pressure was +3.4 mmHg on clonidine HCl extended-release 0.2 mg/day and -5.6 mmHg on clonidine HCl extended-release 0.4 mg/day. The maximum placebo-subtracted mean change in diastolic blood pressure was +3.3 mmHg on clonidine HCl extended-release 0.2 mg/day and -5.4 mmHg on clonidine HCl extended-release 0.4 mg/day. The maximum placebo-subtracted mean change in heart rate was -0.6 beats per minute on clonidine HCl extended-release 0.2 mg/day and -3.0 beats per minute on clonidine HCl extended-release 0.4 mg/day.
The following adverse reactions have been identified during post-approval use of clonidine HCl extended-release. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events exclude those already mentioned in 6.1:
Psychiatric: hallucinations
Cardiovascular: Q-T prolongation
The following have been reported with other oral immediate release formulations of clonidine:
Table 6 Clinically Important Drug Interactions
Concomitant Drug Name or Drug Class | Clinical Rationale | Clinical Recommendation |
Tricyclic antidepressants | Increase blood pressure and may counteract clonidine’s hypotensive effects | Monitor blood pressure and adjust as needed |
Antihypertensive drugs | Potentiate clonidine’s hypotensive effects | Monitor blood pressure and adjust as needed |
CNS depressants | Potentiate sedating effects | Avoid use |
Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) | Potentiate bradycardia and risk of AV block | Avoid use |
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including clonidine HCl extended-release, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting womensmentalhealth.org/adhd-medications.
Risk Summary
Prolonged experience with clonidine HCl extended-release in pregnant women over several decades, based on published literature, including controlled trials, a retrospective cohort study and case reports, have not identified a drug associated risk of major birth defects, miscarriage, and adverse maternal or fetal outcomes. In animal embryofetal studies, increased resorptions were seen in rats and mice administered oral clonidine hydrochloride from implantation through organogenesis at 10 and 5 times, respectively, the maximum recommended human dose (MRHD) given to adolescents on a mg/m2 basis. No developmental effects were seen in rabbits administered oral clonidine hydrochloride during organogenesis at doses up to 3 times the MRHD (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
Oral administration of clonidine hydrochloride to pregnant rabbits during the period of embryo/fetal organogenesis at doses of up to 80 mcg/kg/day (approximately 3 times the oral maximum recommended daily dose [MRHD] of 0.4 mg/day given to adolescents on a mg/m2 basis) produced no developmental effects. In pregnant rats, however, doses as low as 15 mcg/kg/day (1/3 the MRHD given to adolescents on a mg/m2 basis) were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating and throughout gestation. Increased resorptions were not associated with treatment at the same or at higher dose levels (up to 3 times the MRHD) when treatment of the dams was restricted to gestation days 6 to 15. Increases in resorptions were observed in both rats and mice at 500 mcg/kg/day (10 and 5 times the MRHD in rats and mice, respectively) or higher when the animals were treated on gestation days 1 to 14; 500 mcg/kg/day was the lowest dose employed in this study.
Risk Summary
Based on published lactation studies, clonidine hydrochloride is present in human milk at relative infant doses ranging from 4.1% to 8.4% of the maternal weight-adjusted dosage. Although in most cases, there were no reported adverse effects in breastfed infants exposed to clonidine, there is one case report of sedation, hypotonia, and apnea in an infant exposed to clonidine through breast milk. If an infant is exposed to clonidine hydrochloride through breastmilk, monitor for symptoms of hypotension and bradycardia, such as sedation, lethargy, tachypnea and poor feeding (see Clinical Considerations).The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for clonidine HCl extended-release and any potential adverse effects on the breastfed child from clonidine HCl extended-release or from the underlying maternal condition. Exercise caution when clonidine HCl extended-release is administered to a nursing woman.
Monitor breastfeeding infants exposed to clonidine HCl extended-release through breast milk for symptoms of hypotension and/or bradycardia such as sedation, lethargy, tachypnea, and poor feeding.
Infertility
Based on findings in Animal studies revealed that clonidine HCl extended-release may impair fertility in females and males of reproductive potential [see Nonclinical Toxicology (13.1)].
The safety and efficacy of clonidine HCl extended-release in the treatment of ADHD have been established in pediatric patients 6 to 17 years of age. Use of clonidine HCl extended-release in pediatric patients 6 to 17 years of age is supported by three adequate and well-controlled studies; a short-term, placebo-controlled monotherapy trial, a short-term adjunctive therapy trial and a longer-term randomized monotherapy trial [see Clinical Studies (14)]. Safety and efficacy in pediatric patients below the age of 6 years has not been established.
Juvenile Animal Data
In studies in juvenile rats, clonidine hydrochloride alone or in combination with methylphenidate had an effect on bone growth at clinically relevant doses and produced a slight delay in sexual maturation in males at 3 times the maximum recommended human dose (MRHD) for clonidine and methylphenidate.
In a study where juvenile rats were treated orally with clonidine hydrochloride from day 21 of age to adulthood, a slight delay in onset of preputial separation (delayed sexual maturation) was seen in males treated with 300 mcg/kg/day, which is approximately 3 times the MRHD of 0.4 mg/day on a mg/m2 basis. The no-effect dose was 100 mcg/kg/day, which is approximately equal to the MRHD. There was no drug effects on fertility or on other measures of sexual or neurobehavioral development.
In a study where juvenile rats were treated with clonidine alone (300 mcg/kg/day) or in combination with methylphenidate (10 mg/kg/day in females and 50/30 mg/kg/day in males; the dose was lowered from 50 to 30 mg/kg/day in males due to self-injurious behavior during the first week of treatment) from day 21 of age to adulthood, decreases in bone mineral density and mineral content were observed in males treated with 300 mcg/kg/day clonidine alone and in combination with 50/30 mg/kg/day methylphenidate and a decrease in femur length was observed in males treated with the combination at the end of the treatment period. These doses are approximately 3 times the MRHD of 0.4 mg/day clonidine and 54 mg/day methylphenidate on a mg/m2 basis. All these effects in males were not reversed at the end of a 4-week recovery period. In addition, similar findings were seen in males treated with a lower dose of clonidine (30 mcg/kg/day) in combination with 50 mg/kg/day of methylphenidate and a decrease in femur length was observed in females treated with clonidine alone at the end of the recovery period. These effects were accompanied by a decrease in body weight gain in treated animals during the treatment period but the effect was reversed at the end of the recovery period. A delay in preputial separation (sexual maturation) was observed in males treated with the combination treatment of 300 mcg/kg/day clonidine and 50/30 mg/kg/day methylphenidate. There was no effect on reproduction or sperm analysis in these males.
The impact of renal impairment on the pharmacokinetics of clonidine in children has not been assessed. The initial dosage of clonidine HCl extended-release should be based on degree of impairment. Monitor patients carefully for hypotension and bradycardia, and titrate to higher doses cautiously. Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine HCl extended-release following dialysis.
Clonidine HCl extended-release is not a controlled substance and has no known potential for abuse or dependence.
Symptoms
Clonidine overdose: hypertension may develop early and may be followed by hypotension, bradycardia, respiratory depression, hypothermia, drowsiness, decreased or absent reflexes, weakness, irritability and miosis. The frequency of CNS depression may be higher in children than adults. Large overdoses may result in reversible cardiac conduction defects or dysrhythmias, apnea, coma and seizures. Signs and symptoms of overdose generally occur within 30 minutes to two hours after exposure.
Treatment
Consult with a Certified Poison Control Center (1-800-222-1222) for up-to-date guidance and advice.
Clonidine hydrochloride extended-release tablets are a centrally acting alpha2-adrenergic agonist available as 0.1 mg extended-release tablets for oral administration. Each 0.1 mg tablet is equivalent to 0.087 mg of the free base.
The inactive ingredients are colloidal silicon dioxide, hypromellose, lactose monohydrate, magnesium stearate, pregelatinized starch (corn) and sodium lauryl sulfate. The formulation is designed to delay the absorption of active drug in order to decrease peak to trough plasma concentration differences. Clonidine hydrochloride, USP is an imidazoline derivative and exists as a mesomeric compound. The chemical name is 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride. The following is the structural formula:
C9H9Cl2N3•HCl Mol. Wt. 266.56
Clonidine hydrochloride, USP is an odorless, bitter, white, crystalline substance soluble in water and alcohol.
Clonidine stimulates alpha2-adrenergic receptors in the brain. Clonidine is not a central nervous system stimulant. The mechanism of action of clonidine in ADHD is not known.
Clonidine is a known antihypertensive agent. By stimulating alpha2-adrenergic receptors in the brain stem, clonidine reduces sympathetic outflow from the central nervous system and decreases peripheral resistance, renal vascular resistance, heart rate, and blood pressure.
Single-dose Pharmacokinetics in Adults
Immediate-release clonidine hydrochloride and clonidine HCl extended-release have different pharmacokinetic characteristics; dose substitution on a milligram for milligram basis will result in differences in exposure. A comparison across studies suggests that the Cmax is 50% lower for clonidine HCl extended-release compared to immediate-release clonidine hydrochloride.
Following oral administration of an immediate release formulation, plasma clonidine concentration peaks in approximately 3 to 5 hours and the plasma half-life ranges from 12 to 16 hours. The half-life increases up to 41 hours in patients with severe impairment of renal function. Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours.
About 50% of the absorbed dose is metabolized in the liver. Although studies of the effect of renal impairment and studies of clonidine excretion have not been performed with clonidine HCl extended-release, results are likely to be similar to those of the immediate release formulation.
The pharmacokinetic profile of clonidine HCl extended-release administration was evaluated in an open-label, three-period, randomized, crossover study of 15 healthy adult subjects who received three single-dose regimens of clonidine: 0.1 mg of clonidine HCl extended-release under fasted conditions, 0.1 mg of clonidine HCl extended-release following a high fat meal, and 0.1 mg of clonidine immediate-release under fasted conditions. Treatments were separated by one-week washout periods.
Mean concentration-time data from the 3 treatments are shown in Table 7 and Figure 1. After administration of clonidine HCl extended-release, maximum clonidine concentrations were approximately 50% of the clonidine immediate-release maximum concentrations and occurred approximately 5 hours later relative to clonidine immediate-release. Similar elimination half-lives were observed and total systemic bioavailability following clonidine HCl extended-release was approximately 89% of that following clonidine immediate-release.
Food had no effect on plasma concentrations, bioavailability, or elimination half-life.
Table 7 Pharmacokinetic Parameters of Clonidine in Healthy Adult Volunteers
Clonidine Immediate-Release-Fasted n=15 | Clonidine HCl Extended-Release-Fed n=15 | Clonidine HCl Extended-Release-Fasted n=14 | ||||
Parameter | Mean | SD | Mean | SD | MEAN | SD |
Cmax (pg/mL) | 443 | 59.6 | 235 | 34.7 | 258 | 33.3 |
AUCinf (hr*pg/mL) | 7,313 | 1,812 | 6,505 | 1,728 | 6,729 | 1,650 |
hTmax (hr) | 2.07 | 0.5 | 6.80 | 3.61 | 6.50 | 1.23 |
T1/2 (hr) | 12.57 | 3.11 | 12.67 | 3.76 | 12.65 | 3.56 |
Figure 1 Mean Clonidine Concentration-Time Profiles after Single Dose Administration
Multiple-dose Pharmacokinetics in Children and Adolescents
Plasma clonidine concentrations in children and adolescents (0.1 mg bid and 0.2 mg bid) with ADHD are greater than those of adults with hypertension with children and adolescents receiving higher doses on a mg/kg basis. Body weight normalized clearance (CL/F) in children and adolescents was higher than CL/F observed in adults with hypertension. Clonidine concentrations in plasma increased with increases in dose over the dose range of 0.2 to 0.4 mg/day. Clonidine CL/F was independent of dose administered over the 0.2 to 0.4 mg/day dose range. Clonidine CL/F appeared to decrease slightly with increases in age over the range of 6 to 17 years, and females had a 23% lower CL/F than males. The incidence of "sedation-like" AEs (somnolence and fatigue) appeared to be independent of clonidine dose or concentration within the studied dose range in the titration study. Results from the add-on study showed that clonidine CL/F was 11% higher in patients who were receiving methylphenidate and 44% lower in those receiving amphetamine compared to subjects not on adjunctive therapy.
Carcinogenesis
Clonidine HCl was not carcinogenic when administered in the diet of rats (for up to 132 weeks) or mice (for up to 78 weeks) at doses of up to 1,620 (male rats), 2,040 (female rats), or 2,500 (mice) mcg/kg/day. These doses are approximately 20, 25, and 15 times, respectively, the maximum recommended human dose (MRHD) of 0.4 mg/day on a mg/m2 basis.
Mutagenesis
There was no evidence of genotoxicity in the Ames test for mutagenicity or mouse micronucleus test for clastogenicity.
Impairment of Fertility
In a reproduction study fertility of female rats appeared to be adversely affected at dose levels of 500 and 2,000 mcg/kg/day (10 and 40 times the MRHD on a mg/m2 basis). Lower doses have not been adequately evaluated and a no adverse effect level could not be established.
Efficacy of clonidine HCl extended-release in the treatment of ADHD was established in children and adolescents (6 to 17 years) in:
Short-term Monotherapy and Adjunctive Therapy to Psychostimulant Studies for ADHD
The efficacy of clonidine HCl extended-release in the treatment of ADHD was established in 2 (one monotherapy and one adjunctive therapy) placebo-controlled trials in pediatric patients aged 6 to 17, who met DSM-IV criteria of ADHD hyperactive or combined hyperactive/inattentive subtypes. Signs and symptoms of ADHD were evaluated using the investigator administered and scored ADHD Rating Scale-IV-Parent Version (ADHDRS-IV) total score including hyperactive/impulsivity and inattentive subscales.
Study 1 (CLON-301), was an 8-week randomized, double-blind, placebo-controlled, fixed dose study of children and adolescents aged 6 to 17 (N=236) with a 5-week primary efficacy endpoint. Patients were randomly assigned to one of the following three treatment groups: clonidine HCl extended-release (CLON) 0.2 mg/day (N=78), clonidine HCl extended-release 0.4 mg/day (N=80), or placebo (N=78). Dosing for the clonidine HCl extended-release groups started at 0.1 mg/day and was titrated in increments of 0.1 mg/week to their respective dose (as divided doses). Patients were maintained at their dose for a minimum of 2 weeks before being gradually tapered down to 0.1 mg/day at the last week of treatment. At both doses, improvements in ADHD symptoms were statistically significantly superior in clonidine HCl extended-release-treated patients compared with placebo-treated patients at the end of 5 weeks as measured by the ADHDRS-IV total score (Table 8).
Study 2 (CLON-302) was an 8-week randomized, double-blind, placebo-controlled, flexible dose study in children and adolescents aged 6 to 17 (N=198) with a 5-week primary efficacy end point. Patients had been treated with a psychostimulant (methylphenidate or amphetamine) for four weeks with inadequate response. Patients were randomly assigned to one of two treatment groups: clonidine HCl extended-release adjunct to a psychostimulant (N=102) or psychostimulant alone (N=96). The clonidine HCl extended-release dose was initiated at 0.1 mg/day and doses were titrated in increments of 0.1 mg/week up to 0.4 mg/day, as divided doses, over a 3-week period based on tolerability and clinical response. The dose was maintained for a minimum of 2 weeks before being gradually tapered to 0.1 mg/day at the last week of treatment. ADHD symptoms were statistically significantly improved in clonidine HCl extended-release plus stimulant group compared with the stimulant alone group at the end of 5 weeks as measured by the ADHDRS-IV total score (Table 8).
Table 8 Short-Term Trials
Study Number | Treatment Group | Primary Efficacy Measure: ADHDRS-IV Total Score | ||
Mean Baseline Score (SD) | LS Mean Change from Baseline (SE) | Placebo-subtracted Differencea (95% CI) | ||
Study 1 | Clonidine HCl Extended-Release (0.2 mg/day) Clonidine HCl Extended-Release (0.4 mg/day) Placebo | 43.8 (7.47) 44.6 (7.73) 45.0 (8.53) | -15.0 (1.38) -15.6 (1.33) -6.5 (1.35) | -8.5 (-12.2, - 4.8) -9.1 (-12.8, - 5.5) -- |
Study 2 | Clonidine HCl Extended-Release (0.4 mg/day) + Psychostimulant Psychostimulant alone | 38.9 (6.95) 39.0 (7.68) | -15.8 (1.18) -11.3 (1.24) | -4.5 (-7.8, -1.1) -- |
SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: unadjusted confidence interval.
a Difference (drug minus placebo) in least-squares mean change from baseline.
Maintenance Monotherapy for ADHD
Study 3 (SHN-KAP-401), was a double-blind, placebo-controlled, randomized-withdrawal study in children and adolescents aged 6 to 17 years (n=253) with DSM-IV-TR diagnosis of ADHD. The study consisted of a 10-week, open-label phase (4 weeks of dose optimization and 6 weeks of dose maintenance), a 26-week double-blind phase, and a 4-week taper-down and follow-up phase. All patients were initiated at 0.1 mg/day and increased at weekly intervals in increments of 0.1 mg/day until reaching personalized optimal dose (0.1, 0.2, 0.3 or 0.4 mg/day, as divided doses). Eligible patients had to demonstrate treatment response as defined by ≥ 30% reduction in ADHD-RS-IV total score and a Clinical Global Impression-Improvement score of 1 or 2 during the open label phase. Patients who sustained treatment response (n=135) until the end of the open label phase were randomly assigned to one of the two treatment groups, clonidine HCl extended-release (N=68) and Placebo (N=67), to evaluate the long-term efficacy of maintenance dose of clonidine HCl extended-release in the double-blind phase. The primary efficacy endpoint was the percentage of patients with treatment failure defined as a ≥ 30% increase (worsening) in ADHD-RS-IV total score and ≥ 2 points increase (worsening) in Clinical Global Impression – Severity Scale in 2 consecutive visits or early termination for any reason. A total of 73 patients experienced treatment failure in the double-blind phase: 31 patients (45.6%) in the clonidine HCl extended-release group and 42 patients (62.7%) in the placebo group, with a statistically significant difference in the primary endpoint favoring clonidine HCl extended-release (Table 9). The cumulative proportion of patients with treatment failure over time during the double-blind phase is displayed in Figure 2.
Table 9 Treatment Failure: Double-Blind Full Analysis Set (Study 3)
Study 3 | Double-Blind Full Analysis Set | |
Clonidine HCl Extended-Release | Placebo | |
Number of subjects | 68 | 67 |
Number of treatment failures | 31 (45.6%) | 42 (62.7%) |
Basis of Treatment Failure | ||
Clinical criteriaa,b | 11 (16.2%) | 9 (13.4%) |
Lack of efficacyc | 1 (1.5%) | 3 (4.5%) |
Withdrawal of informed assent/consent | 4 (5.9%) | 20 (29.9%) |
Other early terminations | 15 (22.1%) | 10 (14.9%) |
ADHD-RS-IV = Attention Deficit Hyperactivity Disorder-Rating Scale-4th edition; CGI-S = Clinical Global Impression-Severity
a At the same 2 consecutive visits a (1) 30% or greater reduction in ADHD-RS-IV, and (2) 2-point or more increase in CGI-S.
b Two subjects (1 placebo and 1 clonidine HCl extended-release) withdrew consent, but met the clinical criteria for treatment failure.
c Three subjects (all placebo) discontinued the study due to treatment failure, but met only the criterion for ADHD-RS-IV.
Figure 2: Kaplan-Meier Estimation of Cumulative Proportion of Patients with Treatment Failure
(Study 3)
Clonidine HCl extended-release tablets, 0.1 mg, are supplied as white, round biconvex tablets, debossed "A" over “16” on one side and plain on the other side.
They are available as follows:
Bottles of 60: NDC 69238-1426-6
Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Dispense in a tight container.
Advise the patient to read the FDA-approved Patient Labeling (Patient Information)
Dosage and Administration
Advise patients that clonidine HCl extended-release must be swallowed whole, never crushed, cut, or chewed, and may be taken with or without food. When initiating treatment, provide dosage escalation instructions [see Dosage and Administration (2.1)].
Missed Dose
If patients miss a dose of clonidine HCl extended-release, advise them to skip the dose and take the next dose as scheduled and not to take more than the prescribed total daily amount of clonidine HCl extended-release in any 24-hour period [see Dosage and Administration (2.4)].
Hypotension/Bradycardia
Advise patients who have a history of syncope or may have a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration, to avoid becoming dehydrated or overheated [see Warnings and Precautions (5.1)].
Sedation and Somnolence
Instruct patients to use caution when driving a car or operating hazardous machinery until they know how they will respond to treatment with clonidine HCl extended-release. Also advise patients to avoid the use of clonidine HCl extended-release with other centrally active depressants and with alcohol [see Warnings and Precautions (5.2)].
Rebound Hypertension
Advise patients not to discontinue clonidine HCl extended-release abruptly [see Warnings and Precautions (5.3)].
Allergic Reactions
Advise patients to discontinue clonidine HCl extended-release and seek immediate medical attention if any signs or symptoms of a hypersensitivity reaction occur, such as generalized rash, urticaria, or angioedema [see Warnings and Precautions (5.4)].
Pregnancy Registry
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to clonidine HCl extended-release during pregnancy [see Use in Specific Populations (8.1)].
Lactation
Advise breastfeeding women using clonidine HCl extended-release to monitor infants for excess sedation, decreased muscle tone, and respiratory depression and to seek medical care if they notice these signs [see Use in Specific Populations (8.2)].
Fertility
Advise females and males of reproductive potential that clonidine HCl extended-release may impair fertility [see Use in Specific Populations (8.3) and Nonclinical Toxicology (13.1)].
Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807
Rev. 02-2020-01
Clonidine (KLOE-ni-deen) Hydrochloride Extended-Release Tablets
Read the Patient Information that comes with clonidine HCl extended-release tablets before you start taking it and each time you get a refill. There may be new information. This Patient Information leaflet does not take the place of talking to your doctor about your medical condition or treatment.
What are clonidine HCl extended-release tablets?
Clonidine HCl extended-release tablets are a prescription medicine used for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD). Your doctor may prescribe clonidine HCl extended-release tablets alone or together with certain other ADHD medicines.
Who should not take clonidine HCl extended-release tablets?
What should I tell my doctor before taking clonidine HCl extended-release tablets?
Before you take clonidine HCl extended-release tablets, tell your doctor if you:
womensmentalhealth.org/adhdmedications.Tell your doctor about all of the medicines that you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.
Clonidine HCl extended-release tablets and certain other medicines may affect each other causing serious side effects. Sometimes the doses of other medicines may need to be changed while taking clonidine HCl extended-release tablets.
Especially tell your doctor if you take:
Ask your doctor or pharmacist for a list of these medicines, if you are not sure if your medicine is listed above.
Know the medicines that you take. Keep a list of your medicines with you to show your doctor and pharmacist when you get a new medicine.
How should I take clonidine HCl extended-release tablets?
What should I avoid while taking clonidine HCl extended-release tablets?
What are possible side effects of clonidine HCl extended-release tablets?
Clonidine HCl extended-release tablets may cause serious side effects, including:
The most common side effects of clonidine HCl extended-release tablets include:
Tell your doctor if you have any side effects that bother you or that does not go away.
These are not all of the possible side effects of clonidine HCl extended-release tablets. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store clonidine HCl extended-release tablets?
Keep clonidine HCl extended-release tablets and all medicines out of the reach of children.
General information about the safe and effective use of clonidine HCl extended-release tablets
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use clonidine HCl extended-release tablets for a condition for which it was not prescribed.
Do not give clonidine HCl extended-release tablets to other people, even if they have the same symptoms that you have. It may harm them.
This Patient Information leaflet summarizes the most important information about clonidine HCl extended-release tablets. If you would like more information, talk with your doctor.
You can also ask your doctor or pharmacist for information about clonidine HCl extended-release tablets that is written for healthcare professionals.
For more information about clonidine HCl extended-release tablets, go to www.amneal.com or call 1-877-835-5472.
What are the ingredients in clonidine HCl extended-release tablets?
Distributed by:
Amneal Pharmaceuticals LLC
Bridgewater, NJ 08807
Rev. 02-2020-01
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 69238-1426 | CLONIDINE HYDROCHLORIDE (CLONIDINE) TABLET, EXTENDED RELEASE [AMNEAL PHARMACEUTICALS NY LLC] | 14 | Legacy NDC | 20231230_accb2879-7c0e-40d9-bc78-af78fc619609.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69238-1426-6 | EA - Each | 69238-1426 | 604279ff-20be-4bda-894a-e75deea47094 | 1 | 2018-01-12 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69238-1426 | 69238-1426-6 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CLONIDINE HYDROCHLORIDE | W76I6XXF06 | ACTIB |
| SODIUM LAURYL SULFATE | 368GB5141J | IACT |
| LACTOSE MONOHYDRATE | EWQ57Q8I5X | IACT |
| STARCH, CORN | O8232NY3SJ | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
| MAGNESIUM STEARATE | 70097M6I30 | IACT |
| HYPROMELLOSE 2208 (100000 MPA.S) | VM7F0B23ZI | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A210052-001 | CLONIDINE HYDROCHLORIDE | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | c2088c7a36db… | ||
| 2026-09-14 22:38:34 | 2026-08 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | 2017-11-20 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A210052-001 | CLONIDINE HYDROCHLORIDE | 0.1MG | TABLET, EXTENDED RELEASE / ORAL | AB1 | 2017-11-20 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A210052-001 | AB1 | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A210052-001 | AB1 | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A210052-001 | AB1 | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A210052-001 | AB1 | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A210052-001 | AB1 | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A210052-001 | AB1 | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A210052-001 | AB1 | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A210052-001 | AB1 | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A210052-001 | AB1 | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A210052-001 | AB1 | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A210052-001 | AB1 | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A210052-001 | AB1 | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A210052-001 | AB1 | 1 | ea99ee380514… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A210052-001 | AB1 | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A210052-001 | AB1 | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A210052-001 | AB1 | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A210052-001 | AB1 | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A210052-001 | AB1 | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A210052-001 | AB1 | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A210052-001 | AB1 | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A210052-001 | AB1 | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A210052-001 | AB1 | 1 | cb3db0bc1861… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5fddea2c-227a-4970-92ca-01ea9bd5bd1e | accb2879-7c0e-40d9-bc78-af78fc619609 | 2020-02-29 | Warnings, Adverse reactions | accb2879-7c0e-40d9-bc78-af78fc619609 |
Adverse event summaries are temporarily unavailable. Other product information remains available.